{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:57:13Z","timestamp":1715320633684},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1007\/s00115-004-1733-4","type":"journal-article","created":{"date-parts":[[2004,6,23]],"date-time":"2004-06-23T15:02:39Z","timestamp":1088002959000},"page":"801-816","source":"Crossref","is-referenced-by-count":21,"title":["Einsatz von i.\u00a0v. Immunglobulinen in der Neurologie","Use of IV immunoglobulins in neurology"],"prefix":"10.1007","volume":"75","author":[{"given":"M.","family":"Stangel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1733_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.3.CO;2-F","volume":"23","author":"Achiron","year":"2000","unstructured":"Achiron A, Barak Y, Miron S et al. (2000) Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 23:551\u2013555","journal-title":"Muscle Nerve"},{"key":"1733_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","volume":"50","author":"Achiron","year":"1998","unstructured":"Achiron A, Gabbay U, Gilad R et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398\u2013402","journal-title":"Neurology"},{"key":"1733_CR3","first-page":"2498","volume":"27","author":"Al-Mayouf","year":"2000","unstructured":"Al-Mayouf SM, Laxer RM, Schneider R et al. (2000) IVIg therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 27:2498\u20132503","journal-title":"J Rheumatol"},{"key":"1733_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0303-8467(00)00093-7","volume":"102","author":"Alessi","year":"2000","unstructured":"Alessi G, De Reuck J, De Bleecker J et al. (2000) Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg 102:173\u2013175","journal-title":"Clin Neurol Neurosurg"},{"key":"1733_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0387-7604(99)00011-X","volume":"21","author":"Apak","year":"1999","unstructured":"Apak RA, Anlar B, Saatci I (1999) A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 21:279\u2013282","journal-title":"Brain Dev"},{"key":"1733_CR6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00000441-198805000-00005","volume":"295","author":"Arsura","year":"1988","unstructured":"Arsura EL, Bick A, Brunner NG et al. (1988) Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci 295:438\u2013443","journal-title":"Am J Med Sci"},{"key":"1733_CR7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","volume":"44","author":"Azulay","year":"1994","unstructured":"Azulay J-P, Blin O, Pouget J et al. (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 44:429\u2013432","journal-title":"Neurology"},{"key":"1733_CR8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"Bain","year":"1996","unstructured":"Bain PG, Motomura M, Newsom-Davis J et al. (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47:678\u2013683","journal-title":"Neurology"},{"key":"1733_CR9","first-page":"327","volume":"67","author":"Bamberg","year":"1996","unstructured":"Bamberg C, Janzen RWC, Szabados M (1996) Zur Langzeitbehandlung mit 7S-Immunglobulinen bei Myasthenia gravis. Nervenarzt 67:327\u2013332","journal-title":"Nervenarzt"},{"key":"1733_CR10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1517\/13543784.11.7.981","volume":"11","author":"Bien","year":"2002","unstructured":"Bien CG, Elger CE, Wiendl H (2002) Advances in pathogenic concepts and therapeutic agents in Rasmussen\u2019s encephalitis. Expert Opin Invest Drugs 11:981\u2013989","journal-title":"Expert Opin Invest Drugs"},{"key":"1733_CR11","first-page":"A49","volume":"6","author":"Bien","year":"2003","unstructured":"Bien CG, Kuczaty S, Sassen R et al. (2003) Treatment of Rasmussen\u2019s encephalitis with tacrolimus. Neuropediatrics 6:A49\u2013A50","journal-title":"Neuropediatrics"},{"key":"1733_CR12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2796.1995.tb01213.x","volume":"238","author":"Boman","year":"1995","unstructured":"Boman S, Ballen JL, Seggev JS (1995) Dramatic responses to intravenous immunoglobulin in vasculitis. J Intern Med 238:375\u2013377","journal-title":"J Intern Med"},{"key":"1733_CR13","first-page":"2509","volume":"137","author":"Breems","year":"1993","unstructured":"Breems DA, Haas PW de, Visscher F et al. (1993) IVIg as first-choice agent in juvenile dermatomyositis. Ned Tijdschr Geneeskd 137:2509\u20132510","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1733_CR14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","volume":"46","author":"Bril","year":"1996","unstructured":"Bril V, Ilse WK, Pearce R et al. (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome. Neurology 46:100\u2013103","journal-title":"Neurology"},{"key":"1733_CR15","first-page":"1102","volume":"27","author":"Canhao","year":"2000","unstructured":"Canhao H, Fonseca JE, Rosa A (2000) Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren\u2019s syndrome. J Rheumatol 27:1102\u20131103","journal-title":"J Rheumatol"},{"key":"1733_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/jnnp.57.Suppl.69","volume":"57","author":"Cappa","year":"1994","unstructured":"Cappa M, Bertinti E, Balzo P del et al. (1994) High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry (Suppl) 57:69\u201370","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/jnnp.57.Suppl.50","volume":"57","author":"Cherin","year":"1994","unstructured":"Cherin P, Herson S (1994) Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry (Suppl) 57:50\u201354","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A et al. (2002) Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467\u2013474","journal-title":"Arthritis Rheumat"},{"key":"1733_CR19","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","volume":"249","author":"Comi","year":"2002","unstructured":"Comi G, Roveri L, Swan A et al. (2002) A randomised controlle trial of intravonous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370\u20131377","journal-title":"J Neurol"},{"key":"1733_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJM199807303390501","volume":"339","author":"Confavreux","year":"1998","unstructured":"Confavreux C, Hutchinson M, Hours MM et al. (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339:285\u2013291","journal-title":"N Engl J Med"},{"key":"1733_CR21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/WNL.40.2.212","volume":"40","author":"Cook","year":"1990","unstructured":"Cook D, Dalakas M, Galdi A et al. (1990) High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 40:212\u2013214","journal-title":"Neurology"},{"key":"1733_CR22","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"Dalakas","year":"2001","unstructured":"Dalakas M, Fujii M, Li M et al. (2001) High-dose intravenous immune globulin for stiff person syndrome. N Engl J Med 345:1870\u20131876","journal-title":"N Engl J Med"},{"key":"1733_CR23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"Dalakas","year":"2001","unstructured":"Dalakas M, Koffman B, Fujii M et al. (2001) A controlled study of IVIg combined with prednisone in the treatment of IBM. Neurology 56:323\u2013327","journal-title":"Neurology"},{"key":"1733_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971\u2013982","journal-title":"Lancet"},{"key":"1733_CR25","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"1733_CR26","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","volume":"40","author":"Dalakas","year":"1996","unstructured":"Dalakas MC, Quarles RH, Farrer RG et al. (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40:792\u2013795","journal-title":"Ann Neurol"},{"key":"1733_CR27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J et al. (1997) Treatment of inclusion-body myositis wiith IVIg: a double-blind, placebo-controlled study. Neurology 48:712\u2013716","journal-title":"Neurology"},{"key":"1733_CR28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archneur.1994.00540210031010","volume":"51","author":"Dalakas","year":"1994","unstructured":"Dalakas MC, Stein DP, Otero C et al. (1994) Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol 51:861\u2013864","journal-title":"Arch Neurol"},{"key":"1733_CR29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMra023009","volume":"349","author":"Darnell","year":"2003","unstructured":"Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543\u20131554","journal-title":"N Engl J Med"},{"key":"1733_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0002-9343(98)00313-1","volume":"106","author":"Dupond","year":"1999","unstructured":"Dupond JL, Gil H, de Wazieres B (1999) Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren\u2019s syndrome. Am J Med 106:125\u2013125","journal-title":"Am J Med"},{"key":"1733_CR31","first-page":"1032","volume":"25","author":"Durez","year":"1998","unstructured":"Durez P, Tourne L, Feremans W et al. (1998) Dramatic response to intravenous high dose gamma-globulin in refractory vasculitis of the skin associated with Sjogren\u2019s syndrome. J Rheumatol 25:1032\u20131033","journal-title":"J Rheumatol"},{"issue":"1","key":"1733_CR32","first-page":"71","volume":"104","author":"M Duse","year":"1996","unstructured":"Duse M, Notarangelo LD, Tiberti S et al. (1996) Intravenous immune globulin in the treatment of intractable childhood epilepsy. Clin Exp Immunol (Suppl\u00a01) 104:71\u201376","journal-title":"Clin Exp Immunol (Suppl"},{"key":"1733_CR33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"Dyck","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838\u2013845","journal-title":"Ann Neurol"},{"key":"1733_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","volume":"349","author":"Fazekas","year":"1997","unstructured":"Fazekas F, Deisenhammer F, Strasser-Fuchs S et al. (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349:589\u2013593","journal-title":"Lancet"},{"key":"1733_CR35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","volume":"55","author":"Federico","year":"2000","unstructured":"Federico P, Zochodne DW, Hahn AF et al. (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256\u20131262","journal-title":"Neurology"},{"key":"1733_CR36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(94)92152-0","volume":"343","author":"Finkel","year":"1994","unstructured":"Finkel TH, Torok TJ, Ferguson PJ et al. (1994) Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 343:1255-1258","journal-title":"Lancet"},{"key":"1733_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00002826-200003000-00009","volume":"23","author":"Finsterer","year":"2000","unstructured":"Finsterer J, Engelmayer E, Trnka E et al. (2000) Immunoglobulins are effective in pontine myelinolysis. Clin Neuropharmacol 23:110\u2013113","journal-title":"Clin Neuropharmacol"},{"key":"1733_CR38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B et al. (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41:789\u2013796","journal-title":"Ann Neurol"},{"key":"1733_CR39","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1001\/archneur.59.5.766","volume":"59","author":"Gorson","year":"2002","unstructured":"Gorson KC, Ropper AH, Weinberg DH et al. (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766\u2013772","journal-title":"Arch Neurol"},{"key":"1733_CR40","first-page":"29","volume":"10","author":"Gottfried","year":"2000","unstructured":"Gottfried I, Seeber A, Anegg B et al. (2000) High dose IVIg in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10:29\u201335","journal-title":"Eur J Dermatol"},{"key":"1733_CR41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/123.7.1481","volume":"123","author":"Gultekin","year":"2000","unstructured":"Gultekin SH, Rosenfeld MR, Voltz R et al. (2000) Paraneoplastic limbic encephalitis: tumor association, neurological symptoms, and immunological findings in 50 patients. Brain 123:1481\u20131494","journal-title":"Brain"},{"issue":"2","key":"1733_CR42","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1177\/135245850000602S05","volume":"6","author":"J Haas","year":"2000","unstructured":"Haas J (2000) High dose IVIg in the post partum period for prevention of exacerbations in MS. Mult Scler (Suppl\u00a02) 6:S18\u2013S20","journal-title":"Mult Scler (Suppl"},{"key":"1733_CR43","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"Hadden","year":"1998","unstructured":"Hadden RD, Cornblath DR, Hughes RA et al. (1998) Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44:780\u2013788","journal-title":"Ann Neurol"},{"key":"1733_CR44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","volume":"119","author":"Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Zochodne D et al. (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119:1067\u20131077","journal-title":"Brain"},{"key":"1733_CR45","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.46.4.1173","volume":"46","author":"Hahn","year":"1996","unstructured":"Hahn JS, Siegler DJ, Enzmann D (1996) Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology 46:1173\u20131174","journal-title":"Neurology"},{"key":"1733_CR46","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1212\/WNL.44.6.1030","volume":"44","author":"Hart","year":"1994","unstructured":"Hart YM, Cortez M, Andermann F et al. (1994) Medical treatment of Rasmussen\u2019s syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 44:1030\u20131036","journal-title":"Neurology"},{"key":"1733_CR47","first-page":"235","volume":"146","author":"Hebbar","year":"1995","unstructured":"Hebbar M, Hebbar-Savean K, Hachulla E et al. (1995) Participation of cryoglobulinaemia in the severe peripheral neuropathies of primary Sjogren\u2019s syndrome. Ann Interne Med 146:235\u2013238","journal-title":"Ann Med Interne"},{"key":"1733_CR48","first-page":"139","volume":"1","author":"Hermosilla","year":"1996","unstructured":"Hermosilla E, Lagueny A, Vital C et al. (1996) Peripheral neuropathy associated with monoclonal IgG of undetermined significance: clinical, electrophysiologic, pathologic and therapeutic study of 14 cases. J Peripher Nerv Syst 1:139\u2013148","journal-title":"J Peripher Nerv Syst"},{"key":"1733_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","volume":"24","author":"Hilkevich","year":"2001","unstructured":"Hilkevich O, Drory VE, Chapman J et al. (2001) The use of immunoglobulin as maintainance therapy in myasthenia gravis. Clin Neuropharmacol 24:173\u2013176","journal-title":"Clin Neuropharmacol"},{"key":"1733_CR50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/PL00007798","volume":"247","author":"H\u00f6llinger","year":"2000","unstructured":"H\u00f6llinger P, Sturzenegger M (2000) Chronic progressive primary lumbosacral plexus neuritis: MRI findings and response to immunoglobulin therapy. J Neurol 247:143\u2013145","journal-title":"J Neurol"},{"key":"1733_CR51","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"Hughes","year":"2001","unstructured":"Hughes RAC, Bensa S, Willison H et al. (2001) Randomized controlled trial of intravenous immunoglobulin (IVIg) versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195\u2013201","journal-title":"Ann Neurol"},{"key":"1733_CR52","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.WNL.0000096174.86850.7F","volume":"61","author":"Jann","year":"2003","unstructured":"Jann S, Bramerio MA, Beretta S et al. (2003) Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 61:1607\u20131610","journal-title":"Neurology"},{"key":"1733_CR53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"Jayne","year":"2000","unstructured":"Jayne DR, Chapel H, Adu D et al. (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 93:433\u2013439","journal-title":"Q J Med"},{"key":"1733_CR54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-1-4757-9182-2_84","volume":"336","author":"Jayne","year":"1993","unstructured":"Jayne DR, Lockwood CM (1993) Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 336:469\u2013472","journal-title":"Adv Exp Med Biol"},{"key":"1733_CR55","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/rheumatology\/35.11.1150","volume":"35","author":"Jayne","year":"1996","unstructured":"Jayne DR, Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150\u20131153","journal-title":"Br J Rheumatol"},{"key":"1733_CR56","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0025-6196(11)63594-5","volume":"72","author":"Jayne","year":"1997","unstructured":"Jayne DR, Rasmussen N (1997) Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community systemic vasculitis clinical trials study group. Mayo Clin Proc 72:737\u2013747","journal-title":"Mayo Clin Proc"},{"key":"1733_CR57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/1090-3798(98)01005-7","volume":"2","author":"Korinthenberg","year":"1998","unstructured":"Korinthenberg R (1998) Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Eur J Paediatr Neurol 2:57\u201359","journal-title":"Eur J Paediatr Neurol"},{"key":"1733_CR58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1212\/WNL.46.1.247","volume":"46","author":"Krauss","year":"1996","unstructured":"Krauss GL, Campbell ML, Roche KW et al. (1996) Chronic steroid-responsive encephalitis without autoantibodies to glutamate receptor GluR3. Neurology 46:247\u2013249","journal-title":"Neurology"},{"key":"1733_CR59","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1212\/WNL.52.4.738","volume":"52","author":"Leach","year":"1999","unstructured":"Leach JP, Chadwick DW, Miles JB et al. (1999) Improvement in adult-onset Rasmussen\u2019s encephalitis with long- term immunomodulatory therapy. Neurology 52:738\u2013742","journal-title":"Neurology"},{"key":"1733_CR60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/jnnp.57.Suppl.46","volume":"57","author":"Leger","year":"1994","unstructured":"Leger JM, Ben Younes-Chennoufi A, Chassande B et al. (1994) Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry (Suppl) 57:46\u201349","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/brain\/124.1.145","volume":"124","author":"Leger","year":"2001","unstructured":"Leger JM, Chassande B, Musset L et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double blind, placebo-controlled study. Brain 124:145\u2013153","journal-title":"Brain"},{"key":"1733_CR62","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1191\/096120399678841007","volume":"8","author":"Levy","year":"1999","unstructured":"Levy Y, Sherer Y, Ahmed A et al. (1999) A study of 20 SLE patients with intravenous immunoglobulin\u2014clinical and serologic response. Lupus 8:705\u2013712","journal-title":"Lupus"},{"key":"1733_CR63","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.1468-1331.2002.00500.x","volume":"9","author":"Lewanska","year":"2002","unstructured":"Lewanska M, Siger-Zajdel M, Selmaj K (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9:565\u2013572","journal-title":"Eur J Neurol"},{"key":"1733_CR64","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1093\/brain\/124.12.2417","volume":"124","author":"Liguori","year":"2001","unstructured":"Liguori R, Vincent A, Clover L et al. (2001) Morvan\u2019s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124:2417\u20132426","journal-title":"Brain"},{"key":"1733_CR65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/jnnp.63.1.28","volume":"63","author":"Mariette","year":"1997","unstructured":"Mariette X, Chastang C, Clavelou P et al. (1997) A randomised clinical trial comparing interferon-\u03b1 and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 63:28\u201334","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR66","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.10279","volume":"17","author":"Meinck","year":"2002","unstructured":"Meinck H-M, Thompson P (2002) Stiff man syndrome and related conditions. Mov Disord 17:853\u2013866","journal-title":"Mov Disord"},{"key":"1733_CR67","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","volume":"56","author":"Mendell","year":"2001","unstructured":"Mendell JR, Barohn RJ, Freimer ML et al. (2001) Randomised controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445\u2013449","journal-title":"Neurology"},{"key":"1733_CR68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02444000","volume":"243","author":"Meucci","year":"1996","unstructured":"Meucci N, Nobile-Orazio E, Scarlato G (1996) Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol 243:117\u2013120","journal-title":"J Neurol"},{"key":"1733_CR69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jnnp.60.6.699","volume":"60","author":"Molina","year":"1996","unstructured":"Molina JA, Benito-Le\u00f3n J, Bermejo F et al. (1996) Intravenous immunoglobulin therapy in sensory neuropathy associated with Sj\u00f6gren\u2019s syndrome. J Neurol Neurosurg Psychiatry 60:699\u2013699","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2169\/internalmedicine.41.142","volume":"41","author":"Mozuchizuki","year":"2002","unstructured":"Mozuchizuki H, Kamakura K, Masaki T et al. (2002) Motor dominant neuropathy in Sjogren\u2019s syndrome: report of two cases. Intern Med 41:142\u2013146","journal-title":"Intern Med"},{"key":"1733_CR71","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.3.CO;2-2","volume":"20","author":"Muchnik","year":"1997","unstructured":"Muchnik S, Losavio AS, Vidal A et al. (1997) Long term follow up of Lambert Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 20: 678","journal-title":"Muscle Nerve"},{"key":"1733_CR72","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","volume":"56","author":"Noseworthy","year":"2001","unstructured":"Noseworthy JH, O\u2019Brien PC, Petterson TM et al. (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514\u20131522","journal-title":"Neurology"},{"key":"1733_CR73","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.55.8.1135","volume":"55","author":"Noseworthy","year":"2000","unstructured":"Noseworthy JH, O\u2019Brien PC, Weinshenker BG et al. (2000) IV immunoglobulin does not reverse established weakness in MS. A double-blind, placebo-controlled trial. Neurology 55:1135\u20131143","journal-title":"Neurology"},{"key":"1733_CR74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","volume":"21","author":"Nydegger","year":"1999","unstructured":"Nydegger UE, Sturzenegger M (1999) Adverse effects of intravenous immunoglobulin therapy. Drug Saf 21:171\u2013185","journal-title":"Drug Saf"},{"key":"1733_CR75","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2169\/internalmedicine.40.349","volume":"40","author":"Ogawa","year":"2001","unstructured":"Ogawa T, Taguchi T, Tanaka Y et al. (2001) Intravenous immunoglobulin therapy for diabetic amyotrophy. Intern Med 40:349\u2013352","journal-title":"Intern Med"},{"key":"1733_CR76","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0301-2115(98)00231-0","volume":"82","author":"Orvieto","year":"1999","unstructured":"Orvieto R, Achiron R, Rotstein Z et al. (1999) Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 82:191\u2013194","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1733_CR77","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0370-4475(77)80049-X","volume":"7","author":"Pechadre","year":"1977","unstructured":"Pechadre JC, Sauvezie B, Osier C et al. (1977) The treatment of epileptic encephalopathies with gamma globulin in children. Rev Electroencephalogr Neurophysiol Clin 7:443\u2013447","journal-title":"Rev Electroencephalogr Neurophysiol Clin"},{"key":"1733_CR78","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","volume":"74","author":"Pestronk","year":"2003","unstructured":"Pestronk A, Florence J, Miller T et al. (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74:485\u2013489","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","volume":"349","author":"Plasma","year":"1997","unstructured":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group (1997) Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Lancet 349:225\u2013230","journal-title":"Lancet"},{"key":"1733_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0022-510X(99)00072-6","volume":"165","author":"Pradhan","year":"1999","unstructured":"Pradhan S, Gupta RP, Shashank S et al. (1999) Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 165:56\u201361","journal-title":"J Neurol Sci"},{"key":"1733_CR81","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","volume":"52","author":"Qureshi","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS et al. (1999) Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 52:629\u2013632","journal-title":"Neurology"},{"key":"1733_CR82","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","volume":"71","author":"Raphael","year":"2001","unstructured":"Raphael JC, Chevret S, Harboun M et al. (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235\u2013238","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR83","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/mus.10359","volume":"27","author":"Renaud","year":"2003","unstructured":"Renaud S, Gregor M, Fuhr P et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611\u2013615","journal-title":"Muscle Nerve"},{"key":"1733_CR84","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/014107689008301021","volume":"83","author":"Rewald","year":"1990","unstructured":"Rewald E, Jaksic JC (1990) Behcet\u2019s syndrome treated with high-dose intravenous IgG and low-dose aspirin. J R Soc Med 83:652\u2013653","journal-title":"J R Soc Med"},{"key":"1733_CR85","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<614::AID-MUS13>3.0.CO;2-W","volume":"20","author":"Rich","year":"1997","unstructured":"Rich MR, Teener JW, Bird SJ (1997) Treatment of Lambert Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 20:614\u2013615","journal-title":"Muscle Nerve"},{"key":"1733_CR86","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.1995.tb02268.x","volume":"101","author":"Richter","year":"1995","unstructured":"Richter C, Schnabel A, Csernok E et al. (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2\u20137","journal-title":"Clin Exp Immunol"},{"key":"1733_CR87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF02592447","volume":"24","author":"Rijckevorsel-Harmant","year":"1994","unstructured":"Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W et al. (1994) Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind\/dose finding clinical study. Int J Clin Lab Res 24:162\u2013166","journal-title":"Int J Clin Lab Res"},{"key":"1733_CR88","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"Ronager","year":"2001","unstructured":"Ronager J, Ravnborg M, Hermansen I et al. (2001) Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 25:967\u2013973","journal-title":"Artif Organs"},{"key":"1733_CR90","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/bjo.85.11.1287","volume":"85","author":"Seider","year":"2001","unstructured":"Seider N, Beiran I, Scharf J et al. (2001) Intravenous immunoglobulin therapy for resistant ocular Behcet\u2019s disease. Br J Ophthalmol 85:1287\u20131288","journal-title":"Br J Ophthalmol"},{"key":"1733_CR91","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/archneur.59.5.751","volume":"59","author":"Sharma","year":"2002","unstructured":"Sharma KR, Cross J, Ayyar DR et al. (2002) Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 59:751\u2013752","journal-title":"Arch Neurol"},{"key":"1733_CR92","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.410380505","volume":"38","author":"Shillito","year":"1995","unstructured":"Shillito P, Molenaar P, Vincent A et al. (1995) Acquired neuromyotonia: evidence for autoantibodies directed againstK+ channels of peripheral nerves. Ann Neurol 38:714\u2013722","journal-title":"Ann Neurol"},{"key":"1733_CR93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/mus.880160113","volume":"16","author":"Simmons","year":"1993","unstructured":"Simmons Z, Bromberg MB, Feldman EL et al. (1993) Polyneuropathy associated with IgA monoclonal gammopathy undetermined significance. Muscle Nerve 16:77\u201383","journal-title":"Muscle Nerve"},{"key":"1733_CR94","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1600-0404.1998.tb00636.x","volume":"97","author":"Simovic","year":"1998","unstructured":"Simovic D, Gorson KC, Ropper AH (1998) Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand 97:194\u2013200","journal-title":"Acta Neurol Scand"},{"key":"1733_CR95","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0022-510X(02)00343-X","volume":"206","author":"Sorensen","year":"2003","unstructured":"Sorensen PS (2003) The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206:123\u2013130","journal-title":"J Neurol Sci"},{"key":"1733_CR96","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","volume":"9","author":"Sorensen","year":"2002","unstructured":"Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557\u2013563","journal-title":"Eur J Neurol"},{"key":"1733_CR97","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.50.5.1273","volume":"50","author":"Sorensen","year":"1998","unstructured":"Sorensen PS, Wanscher B, Jensen CV et al. (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273\u20131281","journal-title":"Neurology"},{"key":"1733_CR98","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/jnnp.68.1.89","volume":"68","author":"Stangel","year":"2000","unstructured":"Stangel M, Boegner F, Klatt CH et al. (2000) A placebo-controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89\u201392","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00002826-199710000-00002","volume":"20","author":"Stangel","year":"1997","unstructured":"Stangel M, Hartung H-P, Marx P et al. (1997) Side effects of high dose intravenous immunoglobulins. Clin Neuropharmacol 20:385\u2013393","journal-title":"Clin Neuropharmacol"},{"key":"1733_CR100","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","volume":"250","author":"Stangel","year":"2003","unstructured":"Stangel M, Kiefer R, Pette M et al. (2003) Side effects of intravenous immunoglobulins in neurological autoimmune disorders: a prospective study. J Neurol 250:818\u2013821","journal-title":"J Neurol"},{"key":"1733_CR101","doi-asserted-by":"crossref","unstructured":"Strasser-Fuchs S, Fazekas F, Deisenhammer F et al. (2000) The Austrian Immunoglobulin in MS (AIMS) Study: final analysis. Mult Scler (Suppl\u00a02) 6:S9\u2013S13","DOI":"10.1177\/135245850000602S03"},{"key":"1733_CR102","first-page":"327","volume":"35","author":"Sugiyama","year":"2003","unstructured":"Sugiyama N, Hamano S, Koga M (2003) High-dose intravenous immunoglobulin therapy in a child case of Bickerstaff\u2019s brainstem encephalitis. No To Hattatsu 35:327\u2013330","journal-title":"No To Hattatsu"},{"key":"1733_CR103","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1212\/01.WNL.0000046680.47883.7D","volume":"60","author":"Takahashi","year":"2003","unstructured":"Takahashi Y, Takata T, Hoshino M et al. (2003) Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjogren\u2019s syndrome. Neurology 60:503\u2013505","journal-title":"Neurology"},{"key":"1733_CR104","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1345\/aph.18439","volume":"33","author":"Taylor","year":"1999","unstructured":"Taylor CT, Buring SM, Taylor KH (1999) Treatment of Wegener\u2019s granulomatosis with immune globulin: CNS involvement in an adolescent female. Ann Pharmacother 33:1055\u20131059","journal-title":"Ann Pharmacother"},{"key":"1733_CR105","first-page":"391","volume":"10","author":"Tomer","year":"1992","unstructured":"Tomer Y, Shoenfeld Y (1992) Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 10:391\u2013393","journal-title":"Clin Exp Rheumatol"},{"key":"1733_CR106","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/(SICI)1097-4598(199702)20:2<244::AID-MUS20>3.0.CO;2-1","volume":"20","author":"Triggs","year":"1997","unstructured":"Triggs WJ, Young MS, Eskin T et al. (1997) Treatment of idiopathic lumbosacral plexopathy with intravenous immunoglobulin. Muscle Nerve 20:244\u2013246","journal-title":"Muscle Nerve"},{"key":"1733_CR107","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s004150050419","volume":"246","author":"van","year":"1999","unstructured":"Van den Berg JS, Van Engelen BG, Boerman RH et al. (1999) Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J Neurol 246:623\u2013625","journal-title":"J Neurol"},{"key":"1733_CR108","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","volume":"59","author":"van","year":"1995","unstructured":"Van den Berg LH, Kerkhoff H, Oey PL et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248\u2013252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR109","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"Van","year":"1992","unstructured":"Van der Meche FGA, Schmitz PIM, Dutch Guillain-Barr\u00e9 Study Group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. N Engl J Med 326:1123\u20131129","journal-title":"N Engl J Med"},{"key":"1733_CR110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.61.3.316","volume":"61","author":"Van","year":"2003","unstructured":"Van der Meulen MF, Bronner IM, Hoogendijk JE et al. (2003) Polymyositis: an overdiagnosed entity. Neurology 61:316\u2013321","journal-title":"Neurology"},{"key":"1733_CR111","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","volume":"40","author":"van","year":"1990","unstructured":"Van Doorn PA, Brand A, Strengers PFW et al. (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209\u2013212","journal-title":"Neurology"},{"key":"1733_CR112","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0920-1211(94)90061-2","volume":"19","author":"van","year":"1994","unstructured":"Van Engelen BG, Renier WO, Weemaes CM et al. (1994) Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 19:181\u2013190","journal-title":"Epilepsy Res"},{"key":"1733_CR113","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"Van","year":"2004","unstructured":"Van Koningsveld R, Schmitz PIM, Van der Mech\u00e9 FGA et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial. Lancet 363:192\u2013196","journal-title":"Lancet"},{"key":"1733_CR114","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1212\/WNL.44.2.248","volume":"44","author":"Verma","year":"1994","unstructured":"Verma A, Bradley WG (1994) High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy. Neurology 44:248\u2013250","journal-title":"Neurology"},{"key":"1733_CR115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","volume":"56","author":"Vermeulen","year":"1993","unstructured":"Vermeulen M, Van Doorn PA, Brand A et al. (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36\u201339","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1733_CR116","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1056\/NEJM200105103441919","volume":"344","author":"Viguier","year":"2001","unstructured":"Viguier M, Guillevin L, Laroche L (2001) Treatment of parvovirus B19-associated polyarteriitis nodosa with intravenous immune globulin. N Engl J Med 344:1481\u20131482","journal-title":"N Engl J Med"},{"issue":"1","key":"1733_CR117","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s100720200013","volume":"23","author":"F Villani","year":"2002","unstructured":"Villani F, Avanzini G (2002) The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci (Suppl\u00a01) 23:S33-S37","journal-title":"Neurol Sci (Suppl"},{"key":"1733_CR118","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1212\/WNL.56.2.248","volume":"56","author":"Villani","year":"2001","unstructured":"Villani F, Spreafico R, Farina L et al. (2001) Positive response to immunomodulatory therapy in an adult patient with Rasmussen\u2019s encephalitis. Neurology 56:248\u2013250","journal-title":"Neurology"},{"key":"1733_CR119","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/(SICI)1097-4598(200005)23:5<655::AID-MUS1>3.0.CO;2-E","volume":"23","author":"Vincent","year":"2000","unstructured":"Vincent A (2000) Understanding neuromyotonia. Muscle Nerve 23:655\u2013657","journal-title":"Muscle Nerve"},{"key":"1733_CR120","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1136\/pmj.76.891.33","volume":"76","author":"Vinjamuri","year":"2000","unstructured":"Vinjamuri S, Leach JP, Hart IK (2000) Serial perfusion brain tomographic scans detect reversible focal ischaemia in Rasmussen\u2019s encephalitis. Postgrad Med J 76:33\u201335","journal-title":"Postgrad Med J"},{"key":"1733_CR121","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/brain\/118.4.841","volume":"118","author":"Visser","year":"1995","unstructured":"Visser LH, Van der Meche FGA, Van Doorn PA et al. (1995) Guillain-Barre syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barr\u00e9 Study Group. Brain 118:841\u2013847","journal-title":"Brain"},{"key":"1733_CR122","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1474-4422(02)00135-7","volume":"1","author":"Voltz","year":"2002","unstructured":"Voltz R (2002) Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis and therapy. Lancet Neurology 1:294\u2013305","journal-title":"Lancet Neurology"},{"key":"1733_CR123","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1056\/NEJM199906103402303","volume":"340","author":"Voltz","year":"1999","unstructured":"Voltz R, Gultekin SH, Rosenfeld MR et al. (1999) A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340:1788\u20131795","journal-title":"N Engl J Med"},{"key":"1733_CR124","unstructured":"Walsh PJ (1991) Treatment of Rasmussen\u2019s syndrome with intravenous gammaglobulin. In: Andermann F (eds) Chronic encephalitis and epilepsy. Rassmussen\u2019s syndrome. Butterworth-Heinemann, Boston, pp\u00a0201\u2013204"},{"key":"1733_CR125","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"Walter","year":"2000","unstructured":"Walter MC, Lochm\u00fcller H, Toepfer M et al. (2000) High-dose immunoglobulin therapiy in sporadic inclusion body myositis: a double-blind, placebo controlled study. J Neurol 247:22\u201328","journal-title":"J Neurol"},{"key":"1733_CR126","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0303-8467(02)00017-3","volume":"105","author":"Wegner","year":"2002","unstructured":"Wegner B (2002) Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg 105:3\u20138","journal-title":"Clin Neurol Neurosurg"},{"key":"1733_CR127","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0887-8994(96)00016-1","volume":"14","author":"Wise","year":"1996","unstructured":"Wise MS, Rutledge SL, Kuzniecky RI (1996) Rasmussen syndrome and long-term response to gamma globulin. Pediatr Neurol 14:149\u2013152","journal-title":"Pediatr Neurol"},{"key":"1733_CR128","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000073059","volume":"50","author":"Wittstock","year":"2003","unstructured":"Wittstock M, Benecke R, Zettl UK (2003) Therapy with intravenous immunoglobulins: complications and side effects. Eur Neurol 50:172\u2013175","journal-title":"Eur Neurol"},{"key":"1733_CR129","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/mus.10224","volume":"26","author":"Wolfe","year":"2002","unstructured":"Wolfe GI, Barohn RJ, Foster BM et al. (2002) Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26:549\u2013552","journal-title":"Muscle Nerve"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-004-1733-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1733-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-004-1733-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T09:15:42Z","timestamp":1699348542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-004-1733-4"}},"subtitle":["Evidenzbasierter Konsens","Evidence-based consensus"],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":128,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1007\/s00115-004-1733-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}